ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Covid-19 roundup: Manufacturing contract axed for Valneva’s vaccine; Penny stock halts early infection trial

French vaccine company Valneva and German CDMO IDT Biologika have decided to terminate their manufacturing collaboration for Valneva’s Covid-19 vaccine. IDT Biologika was originally tasked with making Valneva’s VLA2001 vaccine, but the deal has been […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Infixion Bioscience is Awarded Third NIH SBIR Phase 1 Grant to Develop Therapeutics for Neurofibromatosis (NF1)

SAN DIEGO, Sept. 20, 2022 /PRNewswire/ — Infixion Bioscience, a pre-clinical drug discovery company focused on developing gene-targeted therapeutics for the rare genetic disorder Neurofibromatosis Type 1 (NF1), announced today the awarding of its third […]


ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach SAN DIEGO, Sept. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care

Speakers will discuss how genomics drives more informed, inclusive, and proactive care SAN DIEGO, Sept. 19, 2022 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that […]

No Picture
News

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022

SAN DIEGO, Sept. 19, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data demonstrating sustained improvements with long-term INGREZZA® (valbenazine) capsules treatment in adults with tardive dyskinesia (TD) at […]